Elyse G. Schechter

University of North Carolina at Chapel Hill

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

University of North Carolina at Chapel Hill

Research Subjects

Cancer, Autophagy & Apoptosis

Research Interests

Elyse G. Schechter has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

Adrienne D. Cox
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
27 shared publications
Channing J. Der
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
27 shared publications
Clint A. Stalnecker
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
27 shared publications
David Harold Drewry
Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, U.S.A.
27 shared publications
Elisa Baldelli
Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
27 shared publications
Emanuel F. Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
27 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
PIKfyve inhibition sensitizes PDAC organoids to RAS ERK-MAPK inhibition
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S11 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
PIKfyve inhibition sensitizes PDAC organoids to RAS ERK-MAPK inhibition
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Combined inhibition of PIKfyve and RAS or MEK durably represses PDAC cell proliferation
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S8 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Combined inhibition of PIKfyve and RAS or MEK durably represses PDAC cell proliferation
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
The PIKfyve inhibitor apilimod impairs autophagic flux in PDAC cells
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S3 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
The PIKfyve inhibitor apilimod impairs autophagic flux in PDAC cells
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
PIKfyve inhibition results in the formation of LAMP-1 positive vacuoles
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S5 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
PIKfyve inhibition results in the formation of LAMP-1 positive vacuoles
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
MEK inhibition synergizes with PIKfyvei to impair proliferation of PDAC cell lines
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S7 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
MEK inhibition synergizes with PIKfyvei to impair proliferation of PDAC cell lines
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Combined inhibition of PIKfyve and the RAS ERK-MAPK pathway induces apoptosis in PDAC cell lines
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S9 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Combined inhibition of PIKfyve and the RAS ERK-MAPK pathway induces apoptosis in PDAC cell lines
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Chemically distinct PIKfyve inhibitors block proliferation and autophagy in PDAC cells
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Chemically distinct PIKfyve inhibitors block proliferation and autophagy in PDAC cells
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Key research resource identifiers
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 1 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Key research resource identifiers
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table 2 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Open Access
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Complete results of Apoptosis Array
Website
Google Scholar
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S10 from Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer
by Jonathan M. DeLiberty, Mallory K. Roach, Clint A. Stalnecker, Ryan Robb, Elyse G. Schechter, Noah L. Pieper, Khalilah E. Taylor, Lily M. Pita, Runying Yang, Scott Bang, et al.
Complete results of Apoptosis Array

Show all